Plain-English translation of NCT03604315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of imaging scan called [18F]Fluorthanatrace PET/CT that may help doctors better detect and monitor cancer. The scan uses a special tracer (a radioactive substance) injected into your bloodstream to highlight areas where cancer cells are active. Researchers want to see if this new imaging method can help doctors understand how well cancer treatments are working.
Current imaging scans don't always show doctors everything they need to know about how active a cancer is or how it's responding to treatment. This medication is designed to target a specific protein found in cancer cells, which could give doctors a clearer picture and help them make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll receive two imaging scans. First, you'll have a standard PET/CT scan (if you haven't had one recently) that takes about 20–30 minutes. At least 20–24 hours later, you'll return for the new imaging scan with the medication, which takes about 1 hour. You'll then have a follow-up check 24 hours after your final scan. The study may continue to track how the new imaging results change if you receive cancer treatment.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Enrollment target
~300 participants
Started
December 2018
Primary completion
June 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lilie Lin
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.